Terms: = Bone cancer AND TET2, Q6N021, MGC125715, KIAA1546, FLJ20032, ENSG00000168769, 54790 AND Treatment
46 results:
1. Role of plasma EBV-DNA load and EBER status on newly diagnosed peripheral T-cell lymphoma.
Chen J; Zhou J; Cheng F; Chen D; Guan F; Zhang E; He J; Cai Z; Zhao Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):181. PubMed ID: 38587664
[TBL] [Abstract] [Full Text] [Related]
2. treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.
Streuer A; Jann JC; Boch T; Mossner M; Riabov V; Schmitt N; Altrock E; Xu Q; Demmerle M; Nowak V; Oblaender J; Palme I; Weimer N; Rapp F; Metzgeroth G; Hecht A; Höger T; Merz C; Hofmann WK; Nolte F; Nowak D
Ann Hematol; 2024 Apr; 103(4):1221-1233. PubMed ID: 38413410
[TBL] [Abstract] [Full Text] [Related]
3. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
4. Multiple Genomic Alterations, Including a Novel
Sahin Y; Wang YL; Pei J; Mansoor N; Styler M; Testa JR; Nejati R
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203475
[TBL] [Abstract] [Full Text] [Related]
5. Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma.
Lorenzo-Guerra SL; Codina-Martínez H; Suárez-Fernández L; Cabal VN; García-Marín R; Riobello C; Vivanco B; Blanco-Lorenzo V; Sánchez-Fernández P; López F; Llorente JL; Hermsen MA
Cells; 2023 Dec; 13(1):. PubMed ID: 38201285
[TBL] [Abstract] [Full Text] [Related]
6. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A; Alkhateeb H; Gangat N
Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
[TBL] [Abstract] [Full Text] [Related]
7. [Clinical Analysis of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang QX; Wang LL; Guan J; Zhou Y; Zhang T; Su F; Chen LQ; Cao Y; Cheng H; Zou L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):896-901. PubMed ID: 37356957
[TBL] [Abstract] [Full Text] [Related]
8. Hypoplastic form of myelodysplastic neoplasm.
Votavová H; Lenertová Z; Votava T; Beličková M
Klin Onkol; 2023; 36(3):206-214. PubMed ID: 37353349
[TBL] [Abstract] [Full Text] [Related]
9. Clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia.
Liu L; Zhang D; Fu Q; Wang J; Yu J; Chen D; Wang F; Guo R; Xie X; Jiang Z; Li Y
Clin Exp Med; 2023 Dec; 23(8):4473-4482. PubMed ID: 37087521
[TBL] [Abstract] [Full Text] [Related]
10. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract] [Full Text] [Related]
11. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
Bewersdorf JP; Rampal RK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
[TBL] [Abstract] [Full Text] [Related]
12. The prognostic role of C-KIT, TET1 and tet2 gene expression in Acute Myeloid Leukemia.
Nabil R; Hassan NM; Abdellateif MS; Gawdat RM; Elshazly SS
Mol Biol Rep; 2023 Jan; 50(1):641-653. PubMed ID: 36371552
[TBL] [Abstract] [Full Text] [Related]
13. Cooperation between KDM6B overexpression and tet2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
Wei Y; Kanagal-Shamanna R; Zheng H; Bao N; Lockyer PP; Class CA; Darbaniyan F; Lu Y; Lin K; Yang H; Montalban-Bravo G; Ganan-Gomez I; Soltysiak KA; Do KA; Colla S; Garcia-Manero G
Leukemia; 2022 Aug; 36(8):2097-2107. PubMed ID: 35697791
[TBL] [Abstract] [Full Text] [Related]
14. [Analysis of clinical significance and prognostic impact of tet2 single nucleotide polymorphism I1762V in patients with acute myeloid leukemia].
Li YW; Guo Z; Wang LL; Zhou L; Lyu XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):241-246. PubMed ID: 35405783
[No Abstract] [Full Text] [Related]
15. Complete bone Marrow Necrosis with Charcot-Leyden Crystals Caused by Myeloid Neoplasm with Mutated NPM1 and tet2.
Saito K; Sato T; Notohara K; Nannya Y; Ogawa S; Ueda Y
Intern Med; 2022 Nov; 61(21):3265-3269. PubMed ID: 35185048
[TBL] [Abstract] [Full Text] [Related]
16. The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.
Song J; Zhang H; Dong N; Zhang X; Hussaini M; Jain A; Moscinski L; Shain K; Baz R; Alsina M; Nishihori T; Zhang L
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e414-e426. PubMed ID: 34998786
[TBL] [Abstract] [Full Text] [Related]
17. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
Hattakitpanitchakul S; Kobbuaklee S; Wudhikarn K; Polprasert C
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4037-4042. PubMed ID: 34967586
[TBL] [Abstract] [Full Text] [Related]
18. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
Pullarkat ST; Wu W; Pullarkat V
Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
[TBL] [Abstract] [Full Text] [Related]
19. [Clinical characteristics and therapeutic effect of TP53 variant in patients with acute leukemia].
Mi R; Guo Z; Liu W; Hu J; Fan R; Chen L; Liu J; Wei X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Oct; 38(10):955-960. PubMed ID: 34625931
[TBL] [Abstract] [Full Text] [Related]
20. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
[TBL] [Abstract] [Full Text] [Related]
[Next]
